A genetically engineered fusion protein, named HMK, composed of pro-apoptotic peptide R8-KLA and HER2 affibody, promoted apoptotic mechanisms in SKBR3 BC cells through the activation of exogenous and endogenous apoptotic pathways [272]. This evidence concerns the gene KL and breast cancer.